Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer
NCT02773524Phase 3Unknown
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Nov 2016
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in gastroesophageal junction cancer comparing Regorafenib with Placebo (2 arms). Primary endpoint: Overall Survival. Status: unknown.
02
Drugs
regorafenib
03
Conditions
gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT02773524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02773524.